The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer.
 
Kimio Yonesaka
No Relationships to Disclose
 
Kenji Hirotani
Employment - Daiichi Sankyo
 
Joachim Von Pawel
No Relationships to Disclose
 
Mircea Dediu
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Roche
Research Funding - Amgen; Lilly; Polaris; Quintiles; Synta
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Teva
 
Shuquan Chen
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Catherine Copigneaux
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst)